Printer Friendly

UNISURGE COMPLETES THIRD ROUND OF FINANCING

 CUPERTINO, Calif., July 15 /PRNewswire/ -- Unisurge Inc., a manufacturer and marketer of surgical instruments for laparoscopic surgery, based here, today announced the completion of multimillion- dollar financing through the sale of Series C Preferred Stock. Financial details were not disclosed.
 This third round of financing was led by several funds introduced to the company by Berkeley International Capital Corp. Other new participants included Dominion Ventures Inc., as well as existing investors Delphi BioVentures, Sequoia Capital, Technology Partners, Venrock Associates, The Vertical Group, C.R. Bard Inc. (NYSE: BCR) and several private investors.
 "We are pleased to have completed this financing in order to expand the sales effort behind our Unisystem(TM) instruments to general surgeons and operating room nurses nationwide," said Robert D. Berkowitz, president and chief executive officer of Unisurge. "The funds will also allow us to build inventory levels and to bring to market the next generation of minimal access surgical devices."
 Industry analysts estimate the rapidly growing laparoscopic surgical instrument market to be more than $1 billion worldwide by next year. Revolutionizing the field of general surgery, laparoscopy is performed through tiny puncture sites made by hollow tubes through which special surgical instruments are used. Laparoscopic surgery is now provided by a growing number of general surgeons for gall bladder removal, appendectomy, hernia repair and localized cancer therapy.
 Unisurge Inc. was founded in 1990 to develop, manufacture and market surgical instruments for laparoscopic surgery. Available as pre- packaged sterilized kits, or as individual tools for specific surgical procedures, the company's Unisystem(TM) instruments have been designed to provide improved surgical control, effectiveness and efficiency in a cost-effective manner.
 -0- 7/15/93
 /CONTACT: Robert D. Berkowitz, president and chief executive officer of Unisurge, 408-996-4700; or Charles Versaggi of Gable/Versaggi Biocommunications, 408-358-4162, for Unisurge/
 (BCR)


CO: Unisurge Inc. ST: California IN: MTC SU:

TM-LH -- SJ003 -- 1765 07/15/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 15, 1993
Words:315
Previous Article:NORTH AMERICAN BIOLOGICALS RECEIVES FDA LICENSE FOR NEW BIOMEDICAL CENTER - $1.7 MILLION IN PLASMA SHIPMENTS FROM OKLAHOMA SITE UNDERWAY
Next Article:GTE MOBILNET COMPLETES UPGRADE OF ITS DIGITAL CELLULAR NETWORK TO INCLUDE DIGITAL SWITCHING AND CELL SITE EQUIPMENT
Topics:


Related Articles
UNISURGE COMPLETES SECOND ROUND OF FINANCING
SYNTEX EXECUTIVE JOINS UNISURGE'S BOARD OF DIRECTORS
UNISURGE NAMES VP-FINANCE, CFO
GROUND ROUND MAKES ANNOUNCEMENT WITH REGARD TO PROPOSED MERGER
Vicinity Corporation Completes Third Round Financing
Home Wireless Networks - Completes Third-Round of Financing.
Pfizer Hospital Products; PHX Technologies; Pilling Weck; Promex; Searle; Sherwood; Solos Endoscopy; Unisurge;.
Uresil Technology; US Endoscopy; US Surgical; Western Surgical; Richard Wolf Medical Instruments;.
GlucoLight Corporation Raises Third Tranche Of "C" Round Financing.
Arash Motor to offer powercar in Middle East early next year.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters